Literature DB >> 35606495

Genetics etiologies and genotype phenotype correlations in a cohort of individuals with central conducting lymphatic anomaly.

Mandi Liu1, Christopher L Smith1, David M Biko2, Dong Li3,4, Erin Pinto1, Nora O'Connor3, Cara Skraban4, Elaine H Zackai4, Hakon Hakonarson3,4, Yoav Dori1, Sarah E Sheppard5,6,7.   

Abstract

Central conducting lymphatic anomaly (CCLA) is a heterogenous disorder caused by disruption of central lymphatic flow that may result in dilation or leakage of central lymphatic channels. There is also a paucity of known genetic diagnoses associated with CCLA. We hypothesized that specific genetic syndromes would have distinct lymphatic patterns and this would allow us to more precisely define CCLA. As a first step toward "precision lymphology", we defined the genetic conditions associated with CCLA by performing a retrospective cohort study. Individuals receiving care through the Jill and Mark Fishman Center for Lymphatic Disorders at the Children's Hospital of Philadelphia between 2016 and 2019 were included if they had a lymphangiogram and clinical genetic testing performed and consented to a clinical registry. In our cohort of 115 participants, 26% received a molecular diagnosis from standard genetic evaluation. The most common genetic etiologies were germline and mosaic RASopathies, chromosomal abnormalities including Trisomy 21 and 22q11.2 deletion syndrome, and PIEZO1-related lymphatic dysplasia. Next, we analyzed the dynamic contrast magnetic resonance lymphangiograms and found that individuals with germline and mosaic RASopathies, mosaic KRASopathies, PIEZO1-related lymphatic dysplasia, and Trisomy 21 had distinct central lymphatic flow phenotypes. Our research expands the genetic conditions associated with CCLA and genotype-lymphatic phenotype correlations. Future descriptions of CCLA should include both genotype (if known) and phenotype to provide more information about disease (gene-CCLA). This should be considered for updated classifications of CCLA by the International Society of Vascular Anomalies.
© 2022. The Author(s), under exclusive licence to European Society of Human Genetics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35606495      PMCID: PMC9436962          DOI: 10.1038/s41431-022-01123-9

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   5.351


  19 in total

Review 1.  Combined and complex vascular malformations.

Authors:  Robert K Clemens; Thomas Pfammatter; Thomas O Meier; Ahmad I Alomari; Beatrice R Amann-Vesti
Journal:  Vasa       Date:  2015-03       Impact factor: 1.961

2.  Dynamic contrast-enhanced MR lymphangiography: feasibility study in swine.

Authors:  Yoav Dori; Menekhem M Zviman; Maxim Itkin
Journal:  Radiology       Date:  2014-07-01       Impact factor: 11.105

3.  Imaging of central lymphatic abnormalities in Noonan syndrome.

Authors:  David M Biko; Breanne Reisen; Hansel J Otero; Chitra Ravishankar; Teresa Victoria; Andrew C Glatz; Jonathan J Rome; Yoav Dori
Journal:  Pediatr Radiol       Date:  2019-01-06

4.  ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.

Authors:  Dong Li; Michael E March; Alvaro Gutierrez-Uzquiza; Charlly Kao; Christoph Seiler; Erin Pinto; Leticia S Matsuoka; Mark R Battig; Elizabeth J Bhoj; Tara L Wenger; Lifeng Tian; Nora Robinson; Tiancheng Wang; Yichuan Liu; Brant M Weinstein; Matthew Swift; Hyun Min Jung; Courtney N Kaminski; Rosetta Chiavacci; Jonathan A Perkins; Michael A Levine; Patrick M A Sleiman; Patricia J Hicks; Janet T Strausbaugh; Jean B Belasco; Yoav Dori; Hakon Hakonarson
Journal:  Nat Med       Date:  2019-07-01       Impact factor: 53.440

5.  Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation.

Authors:  Yoav Dori; Chris Smith; Erin Pinto; Kristen Snyder; Michael E March; Hakon Hakonarson; Jean Belasco
Journal:  Pediatrics       Date:  2020-12       Impact factor: 7.124

6.  Expanded phenotypic spectrum of JAG1-associated diseases: Central conducting lymphatic anomaly with a pathogenic variant in JAG1.

Authors:  Dong Li; Sarah E Sheppard; Christina Peroutka; Caitlin Barnes; Janet R Reid; Christopher L Smith; Yoav Dori; Hakon Hakonarson
Journal:  Clin Genet       Date:  2021-01-12       Impact factor: 4.438

7.  The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome.

Authors:  Sarah Joyce; Kristiana Gordon; Glen Brice; Pia Ostergaard; Rani Nagaraja; John Short; Sandra Moore; Peter Mortimer; Sahar Mansour
Journal:  Eur J Hum Genet       Date:  2015-08-05       Impact factor: 4.246

8.  Variants of SOS2 are a rare cause of Noonan syndrome with particular predisposition for lymphatic complications.

Authors:  Christina Lissewski; Valérie Chune; Francesca Pantaleoni; Alessandro De Luca; Yline Capri; Julia Brinkmann; Francesca Lepri; Paola Daniele; Erika Leenders; Laura Mazzanti; Emanuela Scarano; Francesca Clementina Radio; Kerstin Kutsche; Alma Kuechler; Marion Gérard; Kara Ranguin; Marine Legendre; Yoann Vial; Ineke van der Burgt; Tuula Rinne; Elena Andreucci; Gioia Mastromoro; Maria Cristina Digilio; Hélène Cave; Marco Tartaglia; Martin Zenker
Journal:  Eur J Hum Genet       Date:  2020-08-12       Impact factor: 4.246

9.  Systematic Review of Magnetic Resonance Lymphangiography From a Technical Perspective.

Authors:  Michael Mills; Malou van Zanten; Marco Borri; Peter S Mortimer; Kristiana Gordon; Pia Ostergaard; Franklyn A Howe
Journal:  J Magn Reson Imaging       Date:  2021-02-24       Impact factor: 4.813

10.  Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis.

Authors:  Elisavet Fotiou; Silvia Martin-Almedina; Michael A Simpson; Shin Lin; Kristiana Gordon; Glen Brice; Giles Atton; Iona Jeffery; David C Rees; Cyril Mignot; Julie Vogt; Tessa Homfray; Michael P Snyder; Stanley G Rockson; Steve Jeffery; Peter S Mortimer; Sahar Mansour; Pia Ostergaard
Journal:  Nat Commun       Date:  2015-09-03       Impact factor: 14.919

View more
  1 in total

1.  Guidelines, guidelines everywhere-and still I'm not sure what to do.

Authors:  Alisdair McNeill
Journal:  Eur J Hum Genet       Date:  2022-09       Impact factor: 5.351

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.